{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706664,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ctrv.2025.102956","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T11:04:08Z","timestamp":1746875048000},"page":"102956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: A comprehensive review"],"prefix":"10.1016","volume":"137","author":[{"given":"Taha Koray","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Kavgaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102956_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102956_b0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 Inhibition in Cancer: Beyond Cell Cycle Arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102956_b0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102956_b0020","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2025.102956_b0025","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102956_b0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102956_b0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102956_b0050","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-023-07226-1","article-title":"The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and6inhibitors: a systematic review and meta-analysis","volume":"204","author":"Guven","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102956_b0060","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102956_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231205848","article-title":"CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review","volume":"15","author":"Pavlovic","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102956_b0075","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/ph17070824","article-title":"Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine","volume":"17","author":"Sahin","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/ph14030181","article-title":"Population Pharmacokinetics of Palbociclib in a Real-World Situation","volume":"14","author":"Royer","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ctrv.2025.102956_b0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2019.03.064","article-title":"Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib","volume":"172","author":"Poratti","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102956_b0090","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor\u2013positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102956_b0095","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.ctrv.2025.102956_b0100","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","article-title":"Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4\/6 Inhibitor in Various Solid Tumors","volume":"23","author":"Tripathy","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0105","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.599","article-title":"An integrated assessment of the ADME properties of the CDK4\/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data","volume":"8","author":"James","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ctrv.2025.102956_b0110","doi-asserted-by":"crossref","unstructured":"Hafner M, Mills CE, Subramanian K, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell chemical biology. 2019;26(8):1067-1080. e8.","DOI":"10.1016\/j.chembiol.2019.05.005"},{"key":"10.1016\/j.ctrv.2025.102956_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114225","article-title":"Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS\/MS","volume":"203","author":"Mart\u00ednez-Ch\u00e1vez","year":"2021","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102956_b0120","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/10781552231218959","article-title":"Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4\/6 inhibitors","volume":"30","author":"Kapagan","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ctrv.2025.102956_b0125","article-title":"Implementing a drug interaction protocol for oral systemic anti-cancer therapy with focus on CDK4\/6 inhibitors. JCO Oncology","volume":"20(10_suppl):302\u2013302","author":"Flynn","year":"2024","journal-title":"Practice"},{"key":"10.1016\/j.ctrv.2025.102956_b0130","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919833867","article-title":"Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication","volume":"11","author":"Bellet","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0140","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/1078155220945365","article-title":"Severe rhabdomyolysis induced by possible drug-drug interaction between Ribociclib and Simvastatin","volume":"27","author":"Streicher","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12883-019-1490-4","article-title":"Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report","volume":"19","author":"Nersesjan","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.ctrv.2025.102956_b0150","first-page":"7","article-title":"Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Case Report","author":"Nelson","year":"2017","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102956_b0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1124\/dmd.119.090092","article-title":"Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer","volume":"48","author":"Turner","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.1950","article-title":"Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling","volume":"108","author":"Samant","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102956_b0165","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jcph.1584","article-title":"Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling","volume":"60","author":"Posada","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2025.102956_b0170","article-title":"QTc prolongation across CDK4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"8(5)doi:10.1093\/jncics\/pkae078","author":"Murad","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102956_b0175","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ijc.35255","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database","volume":"156","author":"Li","year":"2025","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102956_b0180","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3390\/cancers16162869","article-title":"Profiling the Cardiovascular Toxicities of CDK4\/6 Inhibitors: A Real-World Pharmacovigilance Study","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2025.102956_b0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.critrevonc.2016.04.012","article-title":"Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art","volume":"102","author":"Barni","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2025.102956_b0190","article-title":"Cardiovascular Events Associated with CDK4\/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database","author":"Zhang","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102956_b0195","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cpdd.356","article-title":"Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions","volume":"6","author":"Sun","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102956_b0200","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1093\/oncolo\/oyae015","article-title":"Proton Pump Inhibitors and Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients With Breast Cancer","volume":"29","author":"Takahashi","year":"2024","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102956_b0205","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00228-022-03435-7","article-title":"The effect of concomitant use of proton pump inhibitors with CDK 4\/6 inhibitors on survival in metastatic breast cancer","volume":"79","author":"\u00c7a\u011flayan","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2025.102956_b0210","article-title":"Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4\/6 inhibitors in advanced HR positive, HER2 negative breast cancer?","volume":"15","author":"de Moraes","year":"2024","journal-title":"A meta-analysis Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102956_b0215","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cpt.940","article-title":"Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations","volume":"104","author":"Samant","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104096","article-title":"Drug-drug interactions between palbociclib and proton pump inhibitors inearly breast cancer: an exploratory analysis of PALLAS (ABCSG-42\/AFT-05\/BIG-14-13\/PrE0109)","volume":"10","author":"Agostinetto","year":"2025","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102956_b0225","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"issue":"4 Suppl 1","key":"10.1016\/j.ctrv.2025.102956_b0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1524-6175.2006.04482.x","article-title":"Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics","volume":"7","author":"Sica","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ctrv.2025.102956_b0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","article-title":"Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes","volume":"14","author":"Fisman","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"48","key":"10.1016\/j.ctrv.2025.102956_b0240","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040684","article-title":"Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes","volume":"103","author":"AlKreathy","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctrv.2025.102956_b0245","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-OT2-01-03","article-title":"Abstract OT2-01-03: ELEVATE: A phase 1b\/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC)","author":"Rugo","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102956_b0250","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102956_b0255","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","article-title":"Phase I\/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)\/HER2(-) Advanced Breast Cancer after Progression on CDK4\/6 Inhibitors (TRINITI-1)","volume":"27","author":"Bardia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102956_b0260","article-title":"Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial","volume":"15(1):2446","author":"G\u00f3mez Tejeda Za\u00f1udo","year":"2024","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102956_b0265","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102956_b0270","article-title":"Adverse kidney outcomes of CDK 4\/6 inhibitors for metastatic breast cancer","volume":"9(1):70","author":"Hanna","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0275","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-022-01206-2","article-title":"Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials","volume":"62","author":"Ji","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102956_b0280","article-title":"CDK4\/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment","volume":"6","author":"Meunier","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2025.102956_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"She","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102956_b0290","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11912-024-01540-7","article-title":"CDK4\/6 inhibitors: The Devil is in the Detail","volume":"26","author":"Magge","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102956_b0295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102956_b0300","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2025.102956_b0305","article-title":"Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management","volume":"8","author":"Khanam","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ctrv.2025.102956_b0310","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.breast.2023.05.002","article-title":"The role of CDK4\/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis","volume":"71","author":"Petrelli","year":"2023","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0315","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1186\/s12885-024-13357-5","article-title":"Activity of CDK4\/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study","volume":"24","author":"Kahraman","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.102956_b0320","article-title":"Standard Versus Reduced CDK4\/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study","volume":"13(23)doi:10.3390\/jcm13237441","author":"Fedele","year":"2024","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102956_b0325","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cancers16101838","article-title":"The Use of Cyclin-Dependent Kinase 4\/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?","volume":"16","author":"Giraudo","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s44276-024-00108-z","article-title":"Overall survival after CDK4\/6 inhibitor dose reduction in women with metastatic breast cancer","volume":"2","author":"Bjerrum","year":"2024","journal-title":"BJC Reports"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102956_b0335","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/jcm14041071","article-title":"Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4\/6 Inhibitors","volume":"14","author":"G\u00fcren","year":"2025","journal-title":"J Clin Med"},{"issue":"37","key":"10.1016\/j.ctrv.2025.102956_b0340","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1080\/14796694.2024.2413841","article-title":"Implementing geriatric assessment for dose optimization of CDK4\/6 inhibitors in older breast cancer patients","volume":"20","author":"Valachis","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2025.102956_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114906","article-title":"Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure","volume":"164","author":"Roncato","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"38","key":"10.1016\/j.ctrv.2025.102956_b0350","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1080\/14796694.2024.2402212","article-title":"The impact of body mass index on the progression-free survival of CDK 4\/6 inhibitors in metastatic breast cancer patients","volume":"20","author":"\u00c7a\u011flayan","year":"2024","journal-title":"Future Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2025.102956_b0355","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1200\/JCO.23.00126","article-title":"Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial","volume":"41","author":"Pfeiler","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0360","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13868","article-title":"Neutrophils as indicators of obesity-associated inflammation: A systematic review and meta-analysis","volume":"26","author":"Gomez-Casado","year":"2025","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102956_b0365","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jnci\/djaa116","article-title":"Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy","volume":"113","author":"Franzoi","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0370","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2468-1253(20)30302-2","article-title":"Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass","volume":"6","author":"Steenackers","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-024-04640-0","article-title":"Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data","volume":"94","author":"Lau","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102956_b0380","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/aogs.14729","article-title":"Breast cancer during pregnancy\u2014The oncologist's point of view","volume":"103","author":"Matikas","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ctrv.2025.102956_b0385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.897951","article-title":"An integrated pharmacological counselling approach to guide decision-making in the treatment with CDK4\/6 inhibitors for metastatic breast cancer","volume":"13","author":"Roncato","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2025.102956_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115479","article-title":"Association of ADME gene polymorphisms on toxicity to CDK4\/6 inhibitors in patients with HR+ HER2-metastatic breast cancer","volume":"167","author":"Peruzzi","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"8\u20139","key":"10.1016\/j.ctrv.2025.102956_b0395","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14622416.2024.2380240","article-title":"Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity","volume":"25","author":"Wang","year":"2024","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102956_b0400","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1634\/theoncologist.2019-0085","article-title":"Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy","volume":"25","author":"Hong","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102956_b0405","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12877-024-05135-6","article-title":"Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors","volume":"24","author":"Oliveira","year":"2024","journal-title":"BMC Geriatr"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102956_b0410","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tips.2019.07.005","article-title":"Artificial Intelligence for Drug Toxicity and Safety","volume":"40","author":"Basile","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102956_b0415","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4\/6 Inhibitors and the Potential for Differential Clinical Activity","volume":"26","author":"Hafner","year":"2019","journal-title":"Cell Chem Biol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T02:21:28Z","timestamp":1747880488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":83,"alternative-id":["S0305737225000787"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102956","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102956"}}